cilostazol has been researched along with daunorubicin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Tamai, I; Toyobuku, H; Tsuji, A; Ueno, K | 1 |
1 review(s) available for cilostazol and daunorubicin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for cilostazol and daunorubicin
| Article | Year |
|---|---|
Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug.
Topics: Animals; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Cilostazol; Daunorubicin; Genes, MDR; Humans; In Vitro Techniques; Intestinal Absorption; Intestine, Small; LLC-PK1 Cells; Male; Permeability; Phosphodiesterase Inhibitors; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Swine; Tetrazoles | 2003 |